Rite Aid warned of risk of delisting from NYSE as shares fall below $1

KEY POINTS

• Rite Aid may be delisted from the New York Stock Exchange.
• Shares of Rite Aid have fallen 64 percent over the past year, down to 75 cents per share as of Thursday's close from $2.11 on Jan. 3, 2018.
• Rite Aid may pursue a reverse stock split if its stock price does not increase.

A pedestrian crosses the street in front of a Rite Aid store in Los Angeles.

Patrick T. Fallon | Bloomberg | Getty Images

Rite Aid is at risk of being delisted from the New York Stock Exchange and considering a reverse stock split to prop its share price above $1 to comply with the exchange's trading rules, the company said Friday.

Shares of the drugstore chain have fallen 64 percent over the past year, down to 75 cents a share as of Thursday's close from $2.11 on Jan. 3, 2018. Rite Aid's stock has hovered under $1 per share over the past month, breaking the NYSE's rule. The exchange notified Rite Aid on Thursday that its average share price was too low and placed its stock at risk of delisting.

Rite Aid has six months from the Jan. 3 notice to boost its average share price above $1 for a month. The company listed a reverse stock split, where companies combine shares to increase the price, as an option "to cure the share price non-compliance."

The delisting warning comes after a string of headaches for the company.

Regulators thwarted Rite Aid's merger with Walgreens Boots Alliance in 2017, forcing Rite Aid to sell a chunk of its stores and leaving the chain with a much smaller footprint than its rivals. Then in 2018, Rite Aid abandoned its planned merger with grocery chain Albertsons amid shareholder opposition, throwing its prospects into question.

A number of Rite Aid shareholders opposed the Albertsons deal, saying the drugstore chain could get a better deal and it was a way for privately held Albertsons to go public without giving Rite Aid much. The companies aborted their merger agreement ahead of a shareholder vote in August.

After the deal collapsed, Rite Aid overhauled its board of directors. It separated the CEO and chairman positions, naming director Bruce Bodaken as chairman and leaving John Standley in place as CEO. It also added three independent directors.